[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

La Merie Publishing: Market Research Reports

Set up in 2002, La Merie Publishing is an authoritative supplier of the cutting-edge information on the biopharmaceutical industry, with a special focus on the research and development pipeline and covering issues related to biologics, including peptides, antibodies, DNA, RNA, proteins and cell therapy.

The company’s service portfolio is represented by various formats and price levels, and includes Brief Reports, Full Reports and Competitor Analysis Reports. Competitor Analysis Reports present no frills, but accurate data on the pipeline of research and development projects for diseases, targets, companies and technologies. The data are fully referenced and delivered in a tabular format. Brief Reports covering Target Pipelines contain all-round assessments of both business and scientific perspectives of new targets. Full Reports present deep analyses of product portfolios, competitive landscape, R&D pipelines and discussions of the pipeline perspectives.

Publications found: 223
Sort by:
Competitor Analysis: PPAR Agonists US$ 520.00

... to print or export an individual report. Despite the tremendous attrition rate of PPAR agonist R&D over the last 20 years, the ones in the market ... delta) Corporate PPAR Agonist Product Portfolios and R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers ...

August 2010 45 pages
R&D Drug Pipeline Database: 2-Months Subscription US$ 2,600.00

... and e-mail support will be provided. Benefits from the R&D Drug Pipeline Database: New database with no historical burden Intuitive use Designed for ... Targets of the Scroll Down Menu: Anti-Infective Antibodies Antibody-Drug Conjugates (ADC) Biologic & Immune Therapy of S. aureus Infections c-MET/HGF ...

August 2010
Competitor Analysis: Streptococcal Vaccines and Antibodies US$ 260.00

... A Streptococcus Group B Streptococcus Other Streptococcal Vaccine & Antibody R&D Agreements Corporate Streptococcal Vaccines & Antibody R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D ...

June 2010 18 pages
Competitor Analysis: P. aeruginosa Vaccines and Therapeutics US$ 260.00

... P. aeruginosa Peptides P. Aeruginosa Small Molecules P. aeruginosa R&D Licensing Agreements Corporate P. aeruginosa Vaccines & Therapeutics R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of ...

June 2010 22 pages
Flat-Rate Subscription to La Merie Reports with 24/7 Online Access US$ 5,200.00

... Merie and available in the online store during the subscription. Among La Merie reports are more than 100 Competitor Analysis reports as well ... sent to ensure customer support. Features of the Flat-Rate Online Access to La Merie Reports: 24/7 access to all La Merie reports Instant online download of report ...

June 2010
Competitor Analysis: HPV Vaccines US$ 195.00

... of the three recommended doses when they were younger. The approved vaccines protect against two or four, respectively, most common types ... a hyperlink leading to the source of information. Index HPV Vaccines Corporate HPV Vaccines R&D Pipelines About La Merie About Competitor Analysis Series The ...

May 2010 18 pages
Oncology Pipeline Database: 1-Year Subscription US$ 2,340.00

Product description Subscription to La Merie's proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive ...

May 2010
Competitor Analysis: Biologic and Immune Therapy of S. aureus Infections US$ 260.00

... a hyperlink leading to the source of information. Index Proteins & peptides Antibodies Vaccines Corporate R&D Pipelines of Biologic and Immuno Therapeutics of S. aureus infections About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS, but concise ...

March 2010 28 pages
Brief Report: Interleukin-17 (IL-17R) and IL-17 Receptor Antagonists US$ 650.00

Product description The present Brief Report about molecules targeting interleukin-17 (IL-17) or its receptor provides an assessment, competitor evaluation and detailed profiles of antibodies and other molecules in development. R&D projects of primarily antibodies targeting IL-17 or IL-17R to treat ...

February 2010 42 pages
Competitor Analysis: BlyS, BAFF & APRIL Antagonists US$ 130.00

... leading to the source of information. Index BlyS, BAFF & APRIL Targeted Therapy Corporate BlyS, BAFF & APRIL R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, ...

February 2010 12 pages
Competitor Analysis: Notch Pathway Inhibitors US$ 130.00

... , R&D Stage and additional comments with a hyperlink leading to the source of information. Index Notch Pathway Inhibitors Corporate Notch Pathway Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise ...

February 2010 10 pages
Oncology Pipeline Database: 6-Month Subscription US$ 1,560.00

Product description Subscription to La Merie's proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive ...

February 2010
Competitor Analysis: PSMA & PSA Targeted Therapy US$ 195.00

... targeted therapy of prostate and other cancers. Prostate-specific antigen (PSA) was discovered more than 20 years ago and has become the ... PSA Targeted Therapy Corporate PSMA & PSA Targeted Therapy R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers ...

January 2010 18 pages
Competitor Analysis: Selective Estrogen Receptor Modulators US$ 195.00

... Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. Index Selective Estrogen Receptor Modulators Corporate SERM R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise ...

January 2010 19 pages
Competitor Analysis: Neurotrophic Growth Factors US$ 520.00

... disease Alzheimer's disease Multiple sclerosis Huntington's disease Ophthalmic diseases Various Corporate Neurotrophic Growth Factor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of ...

December 2009 38 pages
Competitor Analysis: Growth Factors for Bone, Dental, Cartilage and Tendon Repair US$ 390.00

... engineered peptides, antibodies, small molecules or even plasmids. Among the growth stimulators are the BMPs, GDFs, PDGF, PTH receptor agonists, ... , Dental, Cartilage and Tendon Growth Factor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS ...

December 2009 42 pages
Competitor Analysis: Tissue Growth Factors US$ 1,040.00

... description The present Competitive Intelligence Report about tissue growth factors provides a competitor evaluation in the field of molecules such as proteins, peptides ... as HGF, VEGF, TGF, NGF, GDF and quite a number of neurotrophic factors are under development. Apart from proteins as the classical drugs ...

December 2009 57 pages
Competitor Analysis: FGF-R Agonists and Antagonists US$ 234.00

Product description The present Competitive Intelligence Report about TGF-R agonists and antagonists provides a competitor evaluation in the field of transforming growth factor receptor (TGF-R) or TG...

November 2009 20 pages
Competitor Analysis: FGF-R Agonists and Antagonists US$ 390.00

Product description The present Competitive Intelligence Report about FGF-R agonists and antagonists provides a competitor evaluation in the field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound healing, cardiac tissue repair, bone formation or treatment of cancer as of ...

November 2009 37 pages
Competitor Analysis: Proteasome Inhibitors US$ 130.00

... R&D Stage and additional comments with a hyperlink leading to the source of information. Index Velcade Pipeline Proteasome Inhibitors Corporate Proteasome Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise ...

November 2009 14 pages
Competitor Analysis: CXCR and CXCL Agonists and Antagonists US$ 390.00

... The present Competitive Intelligence Report about CXCR agonists and CXCR/CXCL antagonists provides a competitor evaluation in the field of chemokine receptor ... approved and marketed drug is plerixafor (AMD3100), a small molecule inhibitor of the CXCR-4/SDF-1 axis, used for stem cell mobilization. CXCR1 and ...

November 2009 30 pages
R&D Pipeline News - Therapeutic Area Edition: 1-Month Subscription US$ 130.00

... subscription consists of 50 issues, the monthly of four or five issues. R&D Pipeline News Therapeutic Area Edition will keep you up-to-date with the ... , combination products, cell therapy and drug delivery products. The news are retrieved from business as well as scientific communications over all ...

November 1999
R&D Pipeline News - Technology Edition: 1-Month Subscription US$ 130.00

... subscription consists of 50 issues, the monthly of four or five issues. R&D Pipeline News Technology Edition will keep you up-to-date with the latest ... , combination products, cell therapy and drug delivery products. The news are retrieved from business as well as scientific communications over all ...

November 1999

Filters

Search

Categories

2
1
1
4
1
19
27
3
2
1
10
4
21
5
5
100
17

Publishers

223

Regions

223

Price

—

Date

—

Pages

—

Offers

1
4